Capcnamo contains Capecitabine, an oral chemotherapeutic agent used for the treatment of various cancers, including colorectal cancer, breast cancer, and gastric cancer. Capecitabine is a prodrug of 5-fluorouracil (5-FU), which is converted to the active drug preferentially in tumor tissue, allowing targeted anticancer activity. It is available as oral tablets.

Mechanism of Action

• Capecitabine is metabolized in the liver and tumor tissue to 5-fluorouracil (5-FU).

• 5-FU inhibits thymidylate synthase, an enzyme essential for DNA synthesis in rapidly dividing cells.

• This leads to impaired DNA replication and cell death, particularly in cancer cells.

  Uses

  • Treatment of colorectal cancer (both adjuvant and metastatic settings).

  • Treatment of breast cancer, especially metastatic disease.

  • Sometimes used in gastric and pancreatic cancers.

  • Can be used alone or in combination with other chemotherapy agents.

    Adverse Effects

    • Nausea, vomiting, diarrhea

    • Hand-foot syndrome (redness, pain, or peeling of palms/soles)

    • Fatigue or weakness

    • Mouth sores or stomatitis